The Evidence-Based GLP-1 + Peptide Optimization Platform. Use GLP-1 Correctly.
Best Urologists in Malaysia 2020
Get link
Facebook
X
Pinterest
Email
Other Apps
If you are looking for the best urologists in Malaysia, you've come to the right place. Urology is the surgical specialty that focuses on the urinary tracts of males and females, and on the reproductive system of males.
Da Vinci Surgical System
Some of the diseases treated by an urologist are:
Erectile Dysfunction
Fallen Bladder
Bladder Control Problems
Painful Bladder System
Prostate/Bladder Cancer
A testicular mass
Infertility (Male)
Male Circumcision
Urinary Stones
Difficulty Urinating
Stress Incontinence
Here is a list of the best urologists you can find in Malaysia.
Note: This list is in no particular order.
1. Dr. Susan Woo Yoke Yin - Hospital Kuala Lumpur
Da Vinci Surgical System
Address: Jalan Pahang, 50586 Kuala Lumpur, Malaysia.
Contact Tel. Number: 60 3-26156231
Services: Treatments for Kidney related problems, Prostate enlargement, Kidney stones, Prostate Cancer.
Notable Procedure: Da Vinci Surgical System (Robotic surgery).
Consultant Urologists:
Dr. Susan Woo Yoke Yin is the head of department and senior consultant urologist of Hospital Kuala Lumpur.
Dr Tan Guan Hee
Speciality: Robotic Surgery, Urology
Subspeciality: Uro-oncology
Qualifications: MBBS (IMU), MRCS (Edinburgh), MS (UKM), FRCS(Urol) (Glasgow), Malaysian Board of Urology Certified Urologist, Fellowship in Urology (Melbourne), SUO Fellowship in Uro-Oncology (Toronto)
Dr Lim Chei Seng
Speciality: Urology
Qualifications: MBBS(Mal), FRCS(Glasgow), AM(Mal)
Dr Badrulhisham Bahadzor
Speciality: Robotic Surgery, Urology
Qualifications: MB BCh BAO (Ireland), FRCS (Urol) Glasgow, Certified Urologist (MBU)
3. Dato' Dr. Tan Hui Meng - Subang Jaya Medical Centre (SJMC)
Address and Contact Number:Address: 1 Jalan SS12/1A, 47500 Subang Jaya, Selangor, Malaysia.
Google Map: https://goo.gl/maps/sZxpRBzY4cs
Telephone Contact Number: +603 5639 1212
No. of Beds: 443-bedded hospital, over 160 medical specialists | Joint Commission International (JCI) Accreditation
Other Urologists in Subang Jaya Medical Centre | Urologist SJMC:
Conditions treated and procedures performed: Kidney related problems, Prostate enlargement, Kidney stones, Prostate Cancer, Da Vinci Surgical System (Robotic surgery)
4. Dr. Kenneth Koh Beng Hock - Gleneagles (Ampang) Kuala Lumpur
Address and Contact:
Gleneagles Kuala Lumpur
Address: 282 and 286, Jalan Ampang, 50450 Kuala Lumpur, Malaysia.
Telephone Contact Number: +603-4141 3000
Ambulance Line: +603 4141 3131
Other Urologists in Gleneagles Kuala Lumpur:
Dr. Chua Chong Beng - Urologist (Surgeon)
Dr. Lam Hock Shang - Urologist (Surgeon)
Dr. Loh Chit Sin - Urologist (Surgeon)
Dr. Warren Lo - Urologist (Surgeon) | WhatsApp Conditions treated and procedures performed: Kidney related problems, Dialysis, Prostate enlargement, Kidney stones, Prostate Cancer, Da Vinci Surgical System (Robotic surgery).
5. Dr Muhilan – Urology, Stone and Fertility Centre
Services: Treatment of kidney stones, prostate enlargement, sexual health, and male infertility
Web: https://drmuhilan-urologystone-and-fertility-centre.business.site/
Address: Thomson Hospital (Tropicana Medical Centre) 11, Jalan Teknologi Pju 5 Kota Damansara 47810 Petaling Jaya Selangor Malaysia.
Tel: +60 19-311 2078
Dr Muhilan is the consultant urologist for the Urology, Stone and Fertility Centre. They also provide full-fledged male infertility treatments.
Aside from that, they also provide treatments for women’s incontinence and urine infections, with the help of their cutting-edge laser equipment and advanced medication.
Customer Reviews
Urology, Stone and Fertility Centre is recommended by their patients for having a professional doctor who gives honest and detailed explanations, and for giving good advice before and after surgery.
Some patients wrote their reviews and said:
“Very Professional Dr. Dr. Muhilan gives very professional advice and the explanations are clear and easy to follow. Highly recommended”
“A very professional and a caring doctor, his explanation and guidance are very clear. Definitely will listen to his advise and the suggestions to aim for a healthier life.”
6. Dr Hemanth Kumar Ramasamy – Kidney Stone and Urology Clinic
Photo credit: Dr Hemanth Kumar Ramasamy – Kidney Stone and Urology Clinic website
Services: Treatments for Kidney stones prostate enlargement (BPH), urinary tract infections, male fertility, sexually transmitted disease, andrology prostate cancer, bladder cancer, testicular cancer, kidney cancer.
Web: https://dr-hemanth-kumar-ramasamy-kidney-stone-and-urology.business.site/
Address: Persiaran Surian Kota Damansara 47410 Petaling Jaya Selangor Malaysia
Tel: 03-6287 1194 / 010-241 5398
Operating Hours: Mon to Fri: 8:30 am – 5:30 pm | Sat: 9:00 am – 1:30 pm
Kidney Stone and Urology Clinic is headed by Dr Hemanth Kumar Ramasamy. Dr Ramasamy has had over 18 years of experience in the field of medicine, aside from being a member of the Malaysian Urological Association and the Urological Association of Asia.
As one of the best urologists in Malaysia, Dr. Ramasamy also offers services related to uro-oncology, laparoscopic urological surgery, laser surgery, and paediatric urology.
Customer Reviews
Kidney Stone and Urology Clinic is recommended by their patients for having awesome and knowledgeable urologists, good doctor-patient relationships, and good service.
Some patients wrote their reviews and said:
“A wonderful doctor.knowledgeable. Explain to you exactly your problem. I have been treated with other doctors for about one year and do not know what my exact problem is. I recommend Dr.Hemanth”
“Dr. Hemanth is professional but also friendly, caring and a good listener. He is a Great doctor that treated my kidney stone and made it as comfortable as possible. I’m blessed to have met such a person with extraordinary people skills. Thank you Doctor.”
7. Dr Christopher Ho Chee Kong – Oriental Melaka Straits Medical Centre
Oriental Melaka Straits is a 300-bedded, fully-integrated multidisciplinary specialist medical centre.
It was founded in 2015, with a patient-centred goal of meeting needs and expectations by offering good healthcare and aiming for better health.
Dr Christopher Ho Chee Kong is one of its urologists, and together with a team of specialists, they attend to the local community as well as the tourists with their different healthcare services.
The mission of Oriental Melaka Straits Medical Centre is to become the leading hospital that offers value-based quality healthcare in the region, making them one of the best urologists in Malaysia.
Highlights:
Dental centre
Diagnostic imaging centre
Laboratory
Rehabilitation centre
Health screening centre
Customer Reviews
Oriental Melaka Straits Medical Centre is recommended by their patients for having professional doctors and nurses, good attitudes, and the best treatments.
Some patients wrote their reviews and said:
“Friendly, caring doctor. Best treatment. Clean, spacious new hospital”
“One of the best hospital in Melaka. Very efficient, professional, knowledgeable doctors. Price is average, but professional service is high. Especially Nurses looked after my grandpa were very caring, attentive, friendly, kind and helpful.”
Home › GLP-1 Hub > GLP-1 Muscle Loss By Dr. Frank Yap, MD | Last updated: October 2026 | Purpose: evidence and safety education, not individual medical advice GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The ...
Updated: October 27, 2026 | Evidence review: REDEFINE 1, Novo Nordisk disclosures, and current obesity-treatment guidance CagriSema has attracted attention for the amount of weight people lost in the phase 3 REDEFINE 1 trial. A more clinically important question is whether that weight loss also preserves muscle, strength and physical function. The evidence supports a measured conclusion: CagriSema produced substantial fat loss, but the published body-composition results do not establish that it eliminates muscle loss or preserves skeletal muscle better than semaglutide or tirzepatide. The distinction matters because fat mass, lean soft tissue, skeletal muscle and muscle function are related but not interchangeable outcomes. What readers should know In REDEFINE 1, mean weight loss at week 68 was 20.4% using the treatment-policy estimand and 22.7% using the trial-product estimand. A small DXA subgroup analysis attributed approximatel...
Home › GLP-1 Hub By Dr. Frank Yap, MD | Last updated: October 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide and CagriSema: what is and isn't known Do GLP-1s slow biological aging? Safety, side effects and compounding risks Compounded, gray-market and research peptides: what are the r...
Updated October 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that addin...
By Dr. Frank Yap, MD | Published: September 28, 2026 | Last updated: October 2026 | Reference: U.S. FDA labeling | Purpose: evidence and safety education, not individual medical advice Quick Answer In the U.S. in 2026, adult weight-management GLP-1 options include Wegovy (weekly injection), Wegovy HD 7.2 mg (weekly, only after 2.4 mg is tolerated for 4+ weeks), the Wegovy pill (daily), Zepbound (tirzepatide, weekly) and Foundayo (orforglipron, daily pill). The only direct head-to-head trial, SURMOUNT-5, found -20.2% weight loss with tirzepatide vs -13.7% with semaglutide at 72 weeks, but pills and injections should not be ranked across different trials. Pick by goal (weight, heart risk, sleep apnea, liver), route, tolerability and cost, protect muscle with protein and resistance training, and plan for long-term maintenance because weight re...
Does retatrutide cause muscle loss? The available evidence suggests that retatrutide-associated weight loss includes a reduction in lean mass, as occurs with other effective obesity treatments. However, the available studies do not establish how much actual skeletal muscle an individual will lose, whether the loss affects muscle function, or how much can be prevented through nutrition and exercise. In a published Phase 2 body-composition substudy involving adults with type 2 diabetes, researchers observed substantial fat-mass reductions alongside reductions in lean mass. The results do not show that retatrutide uniquely damages muscle, but they also do not justify assuming that very large weight losses will preserve muscle automatically. The practical priority is to pursue fat loss while preserving strength, physical function, adequate nutrition, and as much useful muscle as possible . Evidence updated October 2026. This article is educational and is not a substitute for ind...
Evidence review and editorial analysis | Updated October 29, 2026 The Ozempic era is not ending because semaglutide has stopped working. It is entering a new phase in which more potent weight-loss medicines, oral alternatives, and experimental drugs targeting conditions beyond obesity are expanding what incretin-based medicine might become. Two investigational drugs illustrate how different the next chapter could look. Retatrutide , Eli Lilly's triple hormone receptor agonist, has reported substantial weight loss across several Phase 3 trials. Brenipatide , a longer-acting dual GLP-1/GIP receptor agonist, is being investigated in psychiatric and addiction-related conditions, including alcohol use disorder. Their stories are not equivalent. Retatrutide has generated substantial human efficacy data, including recent Phase 3 results. Brenipatide represents a broader but still unanswered clinical hypothesis: might incretin biology eventually contribute to treatment for ...
Last updated: October 28, 2026 Semaglutide is best known for treating type 2 diabetes and obesity. But a different question is attracting growing scientific attention: could GLP-1 receptor agonists also help people drink less alcohol, smoke fewer cigarettes or experience fewer addictive cravings? The idea is no longer based exclusively on animal experiments or social-media anecdotes. Human clinical trials have now reported reductions in heavy-drinking days, alcohol craving and some measures of nicotine craving. Most notably, a 26-week randomized trial published in The Lancet in May 2026 found that weekly semaglutide, alongside cognitive behavioural therapy, produced a greater reduction in heavy-drinking days than placebo plus therapy in people with alcohol use disorder and obesity. However, the evidence differs substantially by substance. Results for alcohol are encouraging, while smoking-cessation evidence remains preliminary. Research involving cannabis and opioids is a...
Last reviewed: October 2026. This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are in US dollars and are subject to change. Manufacturer savings programs have eligibility rules and may expire. The cost of a GLP-1 medication in 2026 can range from under $200 per month for certain oral formulations or introductory self-pay offers to several hundred dollars per month for ongoing treatment. Insurance may lower the cost considerably, but coverage for obesity treatment is not guaranteed—even when a medication is medically appropriate. This guide compares Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (orforglipron), Ozempic, Mounjaro and other prescription options , with an emphasis on what patients may actually pay. Important: A manufacturer's advertised price is not necessarily your final pharmacy price. Confirm the exact product, prescribed dose, dispensing method, insurance benefit and savings-program e...
GLP-1 & Obesity Medicine Guide • Updated October 2026 Ozempic, Wegovy, Mounjaro and Trulicity are all once-weekly injectable medicines, but they are not the same drug and they are not approved for exactly the same purposes. Ozempic and Wegovy contain semaglutide ; Trulicity contains dulaglutide ; and Mounjaro contains tirzepatide , a dual GIP/GLP-1 receptor agonist. For weight loss , the strongest head-to-head evidence currently favors tirzepatide over semaglutide. In the 72-week SURMOUNT-5 trial, adults with obesity but without diabetes lost an average of 20.2% of body weight with tirzepatide versus 13.7% with semaglutide . For type 2 diabetes , tirzepatide has also produced greater weight loss and HbA1c reduction than semaglutide 1 mg in SURPASS-2, although that trial does not prove that tirzepatide is superior to every semaglutide dose or every patient-specific regimen. At the same time, “best” depends on the goal . Semaglutide has extensive cardiovascular and kid...
.png)
.png)
.png)
Comments